Topical Treatments for Melasma and Post-inflammatory Hyperpigmentation.
| Autor: | Sadick N, Pannu S, Abidi Z, Arruda S |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of drugs in dermatology : JDD [J Drugs Dermatol] 2023 Nov 01; Vol. 22 (11), pp. 1118-1123. |
| DOI: | 10.36849/JDD.7754 |
| Abstrakt: | Background: Dyschromia is one of the most common reasons for patients to seek dermatological care, especially among individuals with skin of color. Most cases present as melasma or post-inflammatory hyperpigmentation (PIH); both are chronic issues requiring long-term treatment. While many pharmaceutical (topical or systemic) or procedural (lasers/chemical peels) options are available, some treatments are not safe/tolerable for long-term use or can induce/exacerbate PIH. Methods: This qualitative review provides an overview of topical treatments for melasma and PIH, including recent data from an investigator-initiated trial of the retinoid tazarotene. Results: Topical hydroquinone (HQ) in the form of triple combination HQ 4%/tretinoin 0.05%/fluocinolone acetonide 0.01% cream is the gold-standard treatment for melasma and PIH but should not be used long-term due to safety concerns. Efficacy data for OTC/cosmeceutical products are limited or lacking. Topical retinoids are efficacious and safe, though dose and formulation differences may affect tolerability. Tazarotene 0.045% polymeric emulsion lotion demonstrated good efficacy, safety, and tolerability over 24 weeks in adult female patients with moderate-to-severe melasma and/or PIH. Conclusions: There are multiple topical treatments available for dyspigmentation. However, many are lacking efficacy data and others are limited by tolerability or safety concerns. Retinoids, such as tazarotene, may be an efficacious and safe treatment for melasma or PIH. J Drugs Dermatol. 2023;22(11):1118-1123 doi:10.36849/JDD.7754. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|